{
    "Clinical Trial ID": "NCT02961790",
    "Intervention": [
        "INTERVENTION 1: ",
        "  High-dose Oxybutynin Chloride Group",
        "  Patients receive higher dose oxybutynin chloride on days 15-49 in the absence of unacceptable toxicity.",
        "INTERVENTION 2: ",
        "  Low-dose Oxybutynin Chloride Group",
        "  Patients receive lower dose oxybutynin chloride PO BID on days 8-49 in the absence of unacceptable toxicity."
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  History of breast cancer, ductal breast carcinoma in situ (DCIS), or lobular carcinoma in situ (LCIS) (currently without evidence of malignant disease) OR a concern about taking estrogen for fear of breast cancer",
        "  Bothersome hot flashes (defined by their occurrence of >= 28 times per week and of sufficient severity to prompt the patient to seek therapeutic intervention)",
        "  Presence of hot flashes for > 30 days prior to study entry",
        "  Ability to complete questionnaire(s) by themselves or with assistance",
        "  Eastern Cooperative Oncology Group (ECOG) performance status (PS) = 0, 1",
        "  Ability to provide informed written consent",
        "  Life expectancy >= 6 months",
        "  Willing to work with the enrolling institution for follow-up (during the active monitoring phase of the study)",
        "Exclusion Criteria:",
        "  Any of the following current (=< 4 weeks prior) or planned therapies:",
        "  Antineoplastic chemotherapy (anti-HER2 agents allowed)",
        "  Androgens",
        "  Estrogens (any delivery route)",
        "  Progestogens",
        "  Tamoxifen, raloxifene and aromatase inhibitors are allowed, but patient must have been on a constant dose for at least 28 days and must not be expected to stop the medication during the study period",
        "  Selective serotonin reuptake inhibitors (SSRIs)/serotonin?norepinephrine reuptake inhibitors (SNRIs), when being used for hot flash management or other indications such as depression, is allowed, assuming the dose will remain unchanged for the study duration",
        "  Gabapentin/pregabalin, when being used for hot flash management (use for other indications, such as pain, is allowed, assuming the dose will remain unchanged for the study duration)",
        "  Clonidine",
        "  Agents with known potent anticholinergic activity; agents with mild-moderate anticholinergic activity are allowed",
        "  Prior use of oxybutynin during the period in which patient has had hot flashes",
        "  Pregnant women",
        "  Nursing women",
        "  History of any of the following contraindications to oxybutynin:",
        "  Uncontrolled gastroesophageal reflux disease (GERD) despite appropriate therapy; if patient has history of GERD, but symptoms are well-controlled with medical treatment, patient is eligible",
        "  Ulcerative colitis",
        "  Narrow-angle glaucoma",
        "  Urinary retention",
        "  Hypersensitivity to oxybutynin or any other components of the product",
        "  Current uncontrolled hyperthyroidism",
        "  Coronary heart disease (angina or prior myocardial infarction)",
        "  Congestive heart failure",
        "  Symptomatic cardiac arrhythmias",
        "  Current uncontrolled hypertension",
        "  Myasthenia gravis",
        "Dementia"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Average Change in Hot Flash Activity Score From Baseline to Week 7 for Low Dose Oxybutynin vs Placebo and for High Dose Oxybutynin vs Placebo",
        "  Average change in hot flash activity score from baseline to Week 7 for Low Dose Oxybutynin vs Placebo. The hot flash activity will be measured by the weekly average hot flash score (Sloan JA, et. al., 2001), which is a composite entity of both frequency and severity of hot flashes (The Hot Flash Diary collects the following information for Day 1- Day 7 of each week: Number of mild hot flashes, Number of moderate hot flashes, Number of severe hot flashes, Number of very severe hot flashes). This is a count, so it can range from 0 to infinity.",
        "  Time frame: Baseline up to day 49",
        "Results 1: ",
        "  Arm/Group Title: High-dose Oxybutynin Chloride Group",
        "  Arm/Group Description: Patients receive higher dose oxybutynin chloride on days 15-49 in the absence of unacceptable toxicity.",
        "  Overall Number of Participants Analyzed: 31",
        "  Mean (Standard Deviation)",
        "  Unit of Measure: score on a scale  -16.9         (15.6)",
        "Results 2: ",
        "  Arm/Group Title: Low-dose Oxybutynin Chloride Group",
        "  Arm/Group Description: Patients receive lower dose oxybutynin chloride PO BID on days 8-49 in the absence of unacceptable toxicity.",
        "  Overall Number of Participants Analyzed: 34",
        "  Mean (Standard Deviation)",
        "  Unit of Measure: score on a scale  -10.6         (7.7)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 2/46 (4.35%)",
        "  Dry mouth 2/46 (4.35%)",
        "Adverse Events 2:",
        "  Total: 0/48 (0.00%)",
        "  Dry mouth 0/48 (0.00%)"
    ]
}